Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
Obesity · 2024
DOI: 10.1002/oby.24002 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift Obesity, 2024. Verfasst von Xin-Hui Pan und 16 weiteren Autor:innen. Beteiligte Einrichtung: Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Hauptthemen laut MEDLINE: Anti-Obesity Agents, Glucagon-Like Peptide-1 Receptor Agonists, Obesity, Overweight. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 100 Literaturangaben. Gefördert von: MOMMENTUM-CVD centre grant to the National University Heart Centre, National University Health System Seed Fund, National Medical Research Council Clinician-Scientist Award Senior Category.
Abstract (Originalsprache)
Objective
This network meta‐analysis evaluates the efficacy and safety of tirzepatide compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss drugs in the treatment of overweight and obesity.
Methods
MEDLINE, Embase, and Cochrane CENTRAL were searched for randomized controlled trials on tirzepatide, GLP‐1 RA, and weight loss drugs approved by the US Food and Drug Administration. A network meta‐analysis was performed, drawing direct and indirect comparisons between treatment groups. Network diagrams and surface under the cumulative ranking curve analysis were performed for primary (≥5%, ≥10%, ≥15%, absolute weight loss) and secondary outcomes and adverse effects.
Results
Thirty‐one randomized controlled trials, involving more than 35,000 patients, were included in this study. Tirzepatide 15 mg ranked in the top three across weight‐related parameters, glycemic profile (glycated hemoglobin), lipid parameters (total cholesterol, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides), and blood pressure. Tirzepatide 15 mg had the highest efficacy compared with placebo for achieving ≥15% weight loss (risk ratio 10.24, 95% CI: 6.42–16.34). As compared to placebo, tirzepatide and GLP‐1 RA across all doses had significant increases in gastrointestinal adverse effects.
Conclusions
The superiority of tirzepatide and GLP‐1 RA in inducing weight loss and their ability to target multiple metabolic parameters render them promising candidates in the treatment of patients with overweight and obesity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
- Ministry of Health Holdings, Ministry of Health, Singapore.
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore.
- Royal College of Surgeons in Ireland & University College Dublin Malaysia Campus, George Town, Malaysia.
- Department of Endocrinology, National University Hospital, Singapore.
- VCU Health Pauley Heart Center, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.
ORCID-Profile: Bryan Tan, Yip Han Chin, Martin Kueh, Georgios K Dimitriadis, Nicholas W S Chew, Carel W Le Roux
Förderung
- MOMMENTUM-CVD centre grant to the National University Heart Centre
- National University Health System Seed Fund
- National Medical Research Council Clinician-Scientist Award Senior Category
- National Medical Research Council Research Training Fellowship
Zitieren
APA
Pan, X. H., Tan, B., Chin, Y. H., Lee, E. C. Z., Kong, G., Chong, B., Kueh, M., Khoo, C. M., Mehta, A., Majety, P., Grandhi, G. R., Dimitriadis, G. K., Foo, R., Chew, N. W. S., Le Roux, C. W., Mamas, M. A., & Chan, M. Y. (2024). Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. https://doi.org/10.1002/oby.24002
Vancouver
Pan XH, Tan B, Chin YH, Lee ECZ, Kong G, Chong B, et al. Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis. Obesity. 2024. doi:10.1002/oby.24002
BibTeX
@article{Pan2024,
author = {Pan, Xin-Hui and Tan, Bryan and Chin, Yip Han and Lee, Ethan Cheng Zhe and Kong, Gwyneth and Chong, Bryan and Kueh, Martin and Khoo, Chin Meng and Mehta, Anurag and Majety, Priyanka and Grandhi, Gowtham R and Dimitriadis, Georgios K and Foo, Roger and Chew, Nicholas W S and Le Roux, Carel W and Mamas, Mamas A and Chan, Mark Y},
title = {Efficacy and safety of tirzepatide, GLP ‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis},
journal = {Obesity},
year = {2024},
doi = {10.1002/oby.24002}
}
EUVIMED